Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Placing

25 Jun 2019 17:19

RNS Number : 4017D
Angle PLC
25 June 2019
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL ("RESTRICTED JURISDICTION"). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES DISCUSSED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR THE REPUBLIC OF IRELAND.

 

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN ANGLE PLC IN ANY JURISDICTION IN WHICH ANY SUCH, OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

25 June 2019

 

ANGLE plc

("ANGLE" or the "Company")

 

Result of Placing

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that, further to the announcement made earlier today, the Company has successfully raised gross proceeds of £18 million by conditionally placing 29,268,294 Placing Shares at a price of 61.5 pence per New Ordinary Share (the "Issue Price") with new and existing investors. 

The Issue Price was the closing mid-market price of an Ordinary Share of 61.5 pence on 24 June 2019.

A circular to Shareholders is expected to be posted shortly, including details of the General Meeting and the Resolutions and will be available on the Company's website, www.angleplc.com.

The General Meeting will be held at 10.00 a.m. on 12 July 2019 at the offices of the Company at 10 Nugent Road, The Surrey Research Park, Guildford, Surrey GU2 7AF.

 

Related Party Transaction

The participation by Jupiter Asset Management Limited ("Jupiter") in the Placing represents a related party transaction under Rule 13 of the AIM Rules as Jupiter is a substantial shareholder in the Company.

The Directors of the Company, having consulted with finnCap in its capacity as the Company's Nominated Adviser for the purposes of the AIM Rules, consider the terms on which Jupiter is to participate in the Placing to be fair and reasonable insofar as the Company's Shareholders are concerned.

General Meeting and Admission

The Placing is conditional, inter alia, upon the passing of the Resolutions at the General Meeting and upon the relevant Admission becoming effective.

Upon Admission the Enlarged Issued Share Capital is expected to be 172,754,816 Ordinary Shares. On this basis, the Placing Shares will represent approximately 16.94 per cent. of the Company's Enlarged Issued Share Capital.

Application will be made for the 29,268,294 Placing Shares to be admitted to trading on AIM.

Subject to the Resolutions having been passed and the Placing Agreement not having been terminated in accordance with its terms, it is anticipated that admission of the Placing Shares will occur at 8.00 a.m. on or around 15 July 2019.

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released earlier today unless the context requires otherwise.

 

For further information:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

Corporate Broking - Alice Lane, Sunila de Silva

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

+44 (0) 203 705 9330

 

Beech Hill Securities (US Broker)

Thomas Lawrence

+1 646 574 3171

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

 

 

This Announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Prior to publication, certain information contained within this Announcement was deemed to constitute inside information for the purposes of Article 7 of MAR. In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. Due to the publication of this Announcement, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROIMMGZVVKDGLZM
Date   Source Headline
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.